Table 3.
Technical parameters.
| Author (Citation) |
Year | Study Type | Study Cohort | Excluded Pts. with Bad Quality MRI | Diagnostic Test | Definition of csPCa | MRI Findings Considered Positive/Bx Thresholds | Bx or RP | Field Strength | ERC Usage | No. of Readers | Total Experience (Years) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Al Salmi * [29] | 2020 | Pro | DNI Bx status | Y | Both | GS ≥ 7 (3 + 4) | DNI | DNI | 3T | N | 2 | DNI |
| Bao * [30] | 2021 | Ret | DNI Bx status | Y | Both | GS ≥ 7 (3 + 4) | PR ≥ 3 | DNI | 3T | N | 4 | 30 |
| Barth * [31] | 2017 | Pro | Bx-naive | Y | Both | GS ≥ 7 (3 + 4) | All | Bx | 3T | Y | 3 | 29 |
| Boesen * [32] | 2018 | Pro | Bx-naive | N | bpMRI | GS ≥ 7 (4 + 3), CCL > 50% for GS 7 (3 + 4) | PR ≥ 3 + PR_all | Both | 3T | N | 1 | 5 |
| Bosaily * [33] | 2020 | Pro | Bx-naive | N | Both | GS ≥ 7(3 + 4), ≥4 mm CCL | LK ≥ 2 | Bx | 1.5T | N | DNI | DNI |
| Brancato * [34] | 2020 | Ret | Bx-naive | N | mpMRI | GS ≥ 7 (3 + 4) | All | Bx | 1.5T | Y | 3 | 25 |
| Brembilla * [35] | 2022 | Ret | DNI Bx status | N | Both | GS ≥ 7 (3 + 4) | All | Bx | 3T | N | 3 | 28 |
| Cai * [36] | 2021 | Ret | Bx-naive | N | bpMRI | GS ≥ 7 (3 + 4) | DNI | Bx | 1.5T | N | 2 | 5 |
| Cereser * [37] | 2020 | Ret | Proven Ca | Y | Both | GS ≥ 7 (3 + 4) | DNI | RP | 3T | N | 2 | 600 cases/250 cases |
| Cho * [38] | 2020 | Ret | Bx-naive | N | Both | GS ≥ 6, V > 0.5 mL | PR ≥ 4 | RP | 3T | N | 2 | 18 |
| Choi * [39] | 2019 | Ret | Proven Ca | N | Both | GS ≥ 7 (3 + 4), EPE, V > 0.5 mL | PR ≥ 3 | Bx | 3T | N | 2 | 20 |
| Christophe * [40] | 2020 | Ret | DNI Bx status | Y | Both | DNI | All | RP | 3T | N | 4 | 17 |
| Di Campli * [41] | 2018 | Ret | Bx-naive | Y | Both | GS ≥ 7 (3 + 4), EPE | PR ≥ 3 (overall), PR ≥ 4 (csPCa) | Both | 1.5T | N | 3 | 11 |
| EL-Adalany * [42] | 2021 | Pro | Bx-naive | Y | Both | GS ≥ 7 (3 + 4), EPE, V > 0.5 mL | All | Both | 3T | N | 2 | 19 |
| Eldred-Evans * [43] | 2020 | Ret | Repeat Bx | Y | Both | GS ≥ 7 (3 + 4), ≥ 6 mm CCL of any GS | LK ≥ 3 | Bx | 3T | N | 1 | 10 |
| Gatti * [44] | 2019 | Ret | Bx-naive | N | Both | DNI | All | Both | 1.5T | N | 6 | DNI |
| Giannarini * [45] | 2021 | Ret | Proven Ca | Y | Both | ≥pT3 | ≥pT3 | RP | 3T | N | 2 | 12 |
| Han * [46] | 2020 | Ret | Bx-naive | Y | Both | GS ≥ 7 (3 + 4) | All | Bx | 3T | N | 2 | 10 |
| Jambor * [47] | 2019 | Pro | Bx-naive | Y | bpMRI | GS ≥ 7 (3 + 4) | LK ≥ 3 | Bx | 1.5T, 3T | N | 3 | DNI |
| Junker * [48] | 2019 | Ret | Bx-naive | N | Both | GS ≥ 7 (4 + 3) | PR ≥ 3 | Both | 1.5T, 3T | N | 1 | DNI |
| Kim * [49] | 2019 | Ret | Bx-naive | Y | bpMRI | GS ≥ 7 (3 + 4) | PR ≥ 3 | Bx | 3T | N | 2 | 19 |
| Knaapila * [50] | 2021 | Pro | Mixed | N | bpMRI | GS ≥ 7 (3 + 4) | LK ≥ 3, LK ≥ 4 | Both | 1.5T, 3T | N | DNI | DNI |
| Kobilnyk * [51] | 2020 | Ret | Bx-naive | N | bpMRI | GS ≥ 7 (3 + 4) | PR ≥ 4 | Bx | 1.5T | N | DNI | DNI |
| Kuhl * [52] | 2017 | Ret | Repeat Bx | Y | Both | GS ≥ 7, PSA ≥ 20, stage > T2b-T3a | PR ≥ 3 | Bx | 3T | N | 4 | DNI |
| Lee * [53] | 2017 | Ret | Bx-naive | N | Both | GG > 3, >5 mm CCL | DNI | Both | 3T | N | 2 | DNI |
| Obmann * [6] | 2018 | Pro | Bx-naive | Y | bpMRI | GS ≥ 7 (3 + 4) | PR ≥ 3 | Bx | 3T | N | 1 | 14 |
| Pesapane * [54] | 2021 | Ret | DNI Bx status | Y | Both | GS ≥ 7 (3 + 4), EPE, GG ≥ 7 (4 + 3) | PR ≥ 3 | Both | 1.5T | Y | 2 | 8 |
| Roh * [55] | 2019 | Ret | Bx-naive | N | mpMRI | GS ≥ 7 (3 + 4) | PR ≥ 3 | Bx | 3T | DNI | 13 | 6–38 |
| Russo * [7] | 2021 | Pro | Bx-naive | N | Both | GS ≥ 7 (3 + 4) | PR ≥ 3, PSAD ≥ 0.12 | Bx | 1.5T | Y | DNI | DNI |
| Scialpi * [56] | 2017 | Ret | Proven Ca | Y | Both | GS ≥ 7 (3 + 4) | All | RP | 3T | N | 2 | DNI |
| Sherrer * [57] | 2019 | Ret | Mixed | N | Both | DNI | DNI | Bx | DNI | N | DNI | DNI |
| Taghipour * [58] | 2018 | Ret | Proven Ca | N | Both | GS ≥ 7 (3 + 4) | All | RP | 3T | Y | 1 | 14 |
| Tamada * [59] | 2021 | Ret | Bx-naive | N | Both | GS > 6 | All | Both | 3T | N | 3 | 42 |
| Thestrup * [60] | 2019 | Pro | Bx-naive | N | Both | GS ≥ 7 (3 + 4) | PR ≥ 3 | Bx | 3T | N | 1 | 6 |
| van der Leest * [18] | 2019 | Pro | Bx-naive | N | Both | GS ≥ 7 (3 + 4) | PR ≥ 3 | Bx | 3T | N | 2 | 30 |
| De Visschere * [61] | 2017 | Ret | Bx-naive | N | Both | GS ≥ 7 (3 + 4) | All | Bx | 3T | N | DNI | DNI |
| Wallstrom * [62] | 2021 | Pro | Bx-naive | Y | Both | DNI | PR ≥ 4 | Bx | 3T | N | 3 | 22 |
| Wang * [63] | 2020 | Ret | Bx-naive | N | Both | GS ≥ 7 (3 + 4) | PR ≥ 3 | Bx | 3T | N | 2 | 10 |
| Wang * [64] | 2021 | Ret | Bx-naive | Y | Both | GS ≥ 7 (3 + 4) | DNI | Bx | 3T | N | 2 | 16 |
| Xu * [12] | 2019 | Ret | Bx-naive | Y | Both | GS ≥ 7 (3 + 4), EPE, V > 0.5 mL | All | Both | 3T | N | 2 | 18 |
| Zawaideh * [16] | 2020 | Ret | Mixed | N | Both | GS ≥ 7 (3 + 4) | LK ≥ 3, LK ≥ 4 | Bx | 1.5T, 3T | N | 1 | DNI |
Pro: prospective, Ret: retrospective, Y/N: yes/no, Bx: biopsy, csPCa: clinically significant prostate cancer, PR: PI-RADS, LK: Likert, PR-3: PI-RADS category 3, EPE: extraprostatic extension, V: lesion volume, CCL: cancer core length, GS: Gleason score, PSAD: PSA density, RP: radical prostatectomy, ERC: endorectal coil, DNI: did not indicate. * = et al.